Non-Alcoholic Fatty Liver Disease (NAFLD) Market Share

Statistics for the 2023 & 2024 Non-Alcoholic Fatty Liver Disease (NAFLD) market share, created by Mordor Intelligence™ Industry Reports. Non-Alcoholic Fatty Liver Disease (NAFLD) share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Home Market Analysis Healthcare Research Pharmaceuticals Research Non-Alcoholic Fatty Liver Disease (NAFLD) Market Market Share

Market Share of Non-Alcoholic Fatty Liver Disease (NAFLD) Industry

The non-alcoholic fatty liver disease market is consolidated in terms of ongoing research and development and pharmaceutical pipeline development. The pharmaceutical landscape for NAFLD is dominated by companies that are heavily investing in developing therapeutics for the condition. Some of the key players are Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Gilead Sciences Inc., AbbVie Inc., and Novo Nordisk AS.

Non-Alcoholic Fatty Liver Disease (NAFLD) Market Leaders

  1. Intercept Pharmaceuticals

  2. Madrigal Pharmaceuticals

  3. Novo Nordisk A/S

  4. Gilead Sciences, Inc.

  5. AbbVie, Inc.

*Disclaimer: Major Players sorted in no particular order

Non-Alcoholic Fatty Liver Disease (NAFLD) Market Concentration

Non-Alcoholic Fatty Liver Disease (NAFLD) Market Report Snapshots

Non-alcoholic Fatty Liver Disease (nafld) Market Size & Share Analysis - Growth, Trends, And Forecasts (2024 - 2029)